Base de dados : MEDLINE
Pesquisa : D04.345.566.802.374 [Categoria DeCS]
Referências encontradas : 101 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 11 ir para página                         

  1 / 101 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27665521
[Au] Autor:Davido B; Salomon J; Dinh A
[Ad] Endereço:Maladies Infectieuses, AP-HP, Hôpital Universitaire Raymond-Poincaré, Garches 92380, France. Electronic address: benjamin.davido@aphp.fr.
[Ti] Título:Is oral pristinamycin effective for the treatment of resistant Gram-positive infections as a relay after initial parenteral antimicrobial therapy?
[So] Source:Int J Antimicrob Agents;48(5):574-575, 2016 Nov.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Pristinamicina/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Tratamento Farmacológico/métodos
Seres Humanos
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Pristinamycin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160926
[St] Status:MEDLINE


  2 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27089829
[Au] Autor:Teng JC; Lingaratnam SM; Trubiano JA; Thursky KA; Slavin MA; Worth LJ
[Ad] Endereço:Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, VIC 3000, Australia. Electronic address: jasmine.teng@petermac.org.
[Ti] Título:Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes.
[So] Source:Int J Antimicrob Agents;47(5):391-6, 2016 May.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Pristinamycin has been used to treat a range of Gram-positive infections, but reported experience in patients with malignancy is limited. This study aimed to evaluate the use of pristinamycin in patients with cancer at an Australian centre. All patients commenced on oral pristinamycin therapy at the Peter MacCallum Cancer Centre between January 2005 and December 2014 were identified using the hospital pharmacy dispensing system. Information on demographics, co-morbidities, cancer diagnosis, infection characteristics, pristinamycin regimen, pristinamycin tolerability and outcomes was collected. The median duration of follow-up was 398 days. In total, 26 patients received pristinamycin, with median age of 61 years and a male predominance (65%). Underlying diagnoses were haematological malignancies (50%) and solid tumours (50%). Pathogens included 13 meticillin-resistant Staphylococcus aureus, 6 vancomycin-resistant Enterococcus faecium, 4 meticillin-resistant Staphylococcus epidermidis, 2 meticillin-susceptible S. aureus and 1 vancomycin-susceptible E. faecium. Infection sites were osteomyelitis (6), skin and soft-tissue (4), intra-abdominal/pelvic abscess (4), bloodstream (3), empyema (3), endocarditis/endovascular (3), prosthesis-related infection (2) and epididymo-orchitis (1). One patient ceased pristinamycin due to nausea. Regarding outcome, 13 patients (50%) were cured of infection, 8 (31%) had suppression and 5 (19%) had relapse. Relapses included 1 endovascular infection, 2 episodes of osteomyelitis, 1 pelvic abscess and 1 skin and soft-tissue infection. Overall, 81% of patients achieved cure or suppression of antibiotic-resistant or complex Gram-positive infections, consistent with published experience in non-cancer populations. A favourable tolerability profile makes oral pristinamycin a viable treatment option, particularly in settings where outpatient management of cancer is the objective.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Farmacorresistência Bacteriana
Enterococcus/efeitos dos fármacos
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Neoplasias/complicações
Pristinamicina/administração & dosagem
Staphylococcus/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Austrália
Enterococcus/classificação
Enterococcus/isolamento & purificação
Feminino
Infecções por Bactérias Gram-Positivas/microbiologia
Infecções por Bactérias Gram-Positivas/patologia
Seres Humanos
Masculino
Meia-Idade
Staphylococcus/classificação
Staphylococcus/isolamento & purificação
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Pristinamycin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170215
[Lr] Data última revisão:
170215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160420
[St] Status:MEDLINE


  3 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26801082
[Au] Autor:Valour F; Boibieux A; Karsenty J; Vallat MP; Braun E; Perpoint T; Biron F; Laurent F; Lustig S; Chidiac C; Ferry T; Lyon Bone and Joint Infection Study Group
[Ad] Endereço:Department of Infectious Diseases, Hospices Civils de Lyon, 103 Grande-Rue de la Croix-Rousse, 69004 Lyon, France French Regional Reference Centre for Bone and Joint Infection, Hospices Civils de Lyon, Lyon, France International Centre for Research in Infectiology, INSERM U1111, Claude Bernard Lyon
[Ti] Título:Pristinamycin in the treatment of MSSA bone and joint infection.
[So] Source:J Antimicrob Chemother;71(4):1063-70, 2016 Apr.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate pristinamycin in the treatment of MSSA bone and joint infection (BJI). PATIENTS AND METHODS: A retrospective, single-centre cohort study (2001-11) investigated outcome in adults receiving pristinamycin for MSSA BJI and pristinamycin-related adverse events (AEs). RESULTS: One hundred and two MSSA BJIs were assessed in 98 patients [chronic infection, 33.3%; and orthopaedic device-related infection (ODI), 67.6%]. Surgery was performed in 77.5% of total cases, and in all but three ODIs, associated with antibiotic therapy of a median total duration of 29.2 weeks. Pristinamycin was prescribed as a part of the initial intensive treatment phase (29.4%) and/or included in final maintenance therapy (83.3%) at a dose of 47.6 (45.5-52.6) mg/kg/day for 9.3 (1.4-20.4) weeks. AEs occurred in 13.3% of patients, consisting of gastrointestinal disorder (76.9%) or allergic reaction (23.1%), leading to treatment interruption in 11 cases. AEs were related to daily dose (OR, 2.733 for each 10 additional mg/kg/day; P = 0.049). After a follow-up of 76.4 (29.6-146.9) weeks, the failure rate was 34.3%, associated with ODI (OR, 4.421; P = 0.006), particularly when the implant was retained (OR, 4.217; P = 0.007). In most patients, the pristinamycin companion drug was a fluoroquinolone (68.7%) or rifampicin (21.7%), without difference regarding outcome. CONCLUSIONS: Pristinamycin is an effective, well-tolerated alternative therapeutic option in MSSA BJI, on condition that a daily dosage of 50 mg/kg is respected.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Artrite Infecciosa/tratamento farmacológico
Artrite Infecciosa/microbiologia
Doenças Ósseas Infecciosas/tratamento farmacológico
Doenças Ósseas Infecciosas/microbiologia
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Pristinamicina/uso terapêutico
Infecções Estafilocócicas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Antibacterianos/farmacologia
Artrite Infecciosa/mortalidade
Doenças Ósseas Infecciosas/mortalidade
Estudos de Coortes
Terapia Combinada
Comorbidade
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Pristinamicina/farmacologia
Infecções Estafilocócicas/microbiologia
Infecções Estafilocócicas/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Pristinamycin)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160124
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dkv457


  4 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26376468
[Au] Autor:Tian J; Yang J; Li L; Ruan L; Wei W; Zheng G; Zhao W; Chen J; Jiang W; Ge M; Lu Y
[Ad] Endereço:Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, PR China.
[Ti] Título:The complete genome sequence of a high pristinamycin-producing strain Streptomyces pristinaespiralis HCCB10218.
[So] Source:J Biotechnol;214:45-6, 2015 Nov 20.
[Is] ISSN:1873-4863
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Streptomyces pristinaespiralis produces the streptogramin-like antibiotic pristinamycin, which is a mixture of two structurally different components: pristinamycin I (PI) and pristinamycin II (PII). Herein, we report the complete genome sequence of a high pristinamycin-producing strain HCCB10218 (8.5 Mb) obtained by using PacBio RSII combined with Illumina HiSeq 2500 sequencing system. The genome sequence presented here provides clues for the mechanism underlying the higher pristinamycin production of HCCB10218.
[Mh] Termos MeSH primário: Genoma Bacteriano/genética
Pristinamicina/metabolismo
Streptomyces/genética
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: DNA Bacteriano/análise
DNA Bacteriano/genética
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA, Bacterial); 0 (Pristinamycin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151114
[Lr] Data última revisão:
151114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150917
[St] Status:MEDLINE


  5 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26202178
[Au] Autor:Viel S; Garnier L; Joly E; Rouzaire P; Nosbaum A; Pralong P; Faudel A; Rioufol C; Bienvenu F; Bienvenu J; Berard F
[Ad] Endereço:Laboratoire d'Immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
[Ti] Título:The basophil activation test: a sensitive test in the diagnosis of allergic immediate hypersensitivity to pristinamycin.
[So] Source:Int Arch Allergy Immunol;167(2):94-8, 2015.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Immediate hypersensitivity (IHS) reactions to macrolides and to macrolide-derived antibiotics like pristinamycin are uncommon. In this context, there is little data available to appreciate the true value of biological tools regarding the diagnosis of immediate allergy to pristinamycin. Here we assess the clinical usefulness of the basophil activation test (BAT) to differentiate allergic from nonallergic IHS to pristinamycin. Thirty-six patients were tested with skin tests as the gold standard and BAT. The BAT achieved a sensitivity of 76% and a specificity of 100%, implying an absence of false positive results. Multicenter studies remain to be performed to better define the sensitivity, specificity and interlaboratory variation of BAT in the diagnosis of allergy to pristinamycin and macrolides.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Antibacterianos/imunologia
Teste de Degranulação Basófila/métodos
Hipersensibilidade a Drogas/diagnóstico
Hipersensibilidade a Drogas/etiologia
Hipersensibilidade Imediata/diagnóstico
Hipersensibilidade Imediata/etiologia
Pristinamicina/efeitos adversos
Pristinamicina/imunologia
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Idoso
Antibacterianos/administração & dosagem
Teste de Degranulação Basófila/estatística & dados numéricos
Estudos de Casos e Controles
Árvores de Decisões
Hipersensibilidade a Drogas/imunologia
Feminino
Seres Humanos
Hipersensibilidade Imediata/imunologia
Masculino
Meia-Idade
Pristinamicina/administração & dosagem
Testes Cutâneos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Pristinamycin)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150904
[Lr] Data última revisão:
150904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150724
[St] Status:MEDLINE
[do] DOI:10.1159/000435812


  6 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26187956
[Au] Autor:Mast Y; Guezguez J; Handel F; Schinko E
[Ad] Endereço:Department of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, Faculty of Science, University of Tübingen, Tübingen, Germany yvonne.mast@biotech.uni-tuebingen.de.
[Ti] Título:A Complex Signaling Cascade Governs Pristinamycin Biosynthesis in Streptomyces pristinaespiralis.
[So] Source:Appl Environ Microbiol;81(19):6621-36, 2015 Oct.
[Is] ISSN:1098-5336
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pristinamycin production in Streptomyces pristinaespiralis Pr11 is tightly regulated by an interplay between different repressors and activators. A γ-butyrolactone receptor gene (spbR), two TetR repressor genes (papR3 and papR5), three SARP (Streptomyces antibiotic regulatory protein) genes (papR1, papR2, and papR4), and a response regulator gene (papR6) are carried on the large 210-kb pristinamycin biosynthetic gene region of Streptomyces pristinaespiralis Pr11. A detailed investigation of all pristinamycin regulators revealed insight into a complex signaling cascade, which is responsible for the fine-tuned regulation of pristinamycin production in S. pristinaespiralis.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Regulação Bacteriana da Expressão Gênica
Pristinamicina/biossíntese
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Streptomyces/genética
Fatores de Transcrição/genética
Fatores de Transcrição/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Pristinamycin); 0 (Transcription Factors)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160401
[Lr] Data última revisão:
160401
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150719
[St] Status:MEDLINE
[do] DOI:10.1128/AEM.00728-15


  7 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26065256
[Au] Autor:Jin QC; Shen N; Yin H; Yang Y; Jin ZH
[Ti] Título:[DNA shuffling of ptr resistance gene leads to improved pristinamycin production in Streptomyces pristinaespiralis].
[So] Source:Mol Biol (Mosk);49(2):289-96, 2015 Mar-Apr.
[Is] ISSN:0026-8984
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In order to enhance pristinamycin production, six homologous ptr genes from high pristinamycin-producing strains of Streptomyces pristinaespiralis were selected for DNA shuffling, and the reason for the altered activities of the shuffled ptr gene was speculated by sequence alignment. The highest pristinamycin yield of 0.12 g/L was achieved with a sixfold increase in strain sps16 obtained by DNA shuffling when compared to ancestral strain ATCC 25486. Sequence analysis of theptr gene variant from the sps16 strain indicated that five mutations (H16P, N63D, T75P, Q107R, and P435A) were introduced into the gene, two of them (N63D and T75P) located in the second of the 14 transmembrane segments (TMS). Prediction of the secondary structure of the gene product indicated that mutations at the N-terminus resulted in the shortening of the corresponding α-helix, while the mutation at the C-terminus lengthened the helix. In conclusion, combination of DNA shuffling with genome shuffling is an effective breeding strategy for increasing the antibiotic yield by directed evolution of target genes.
[Mh] Termos MeSH primário: Proteínas de Bactérias/genética
Embaralhamento de DNA
DNA Bacteriano/genética
Farmacorresistência Bacteriana/genética
Proteínas de Membrana/genética
Pristinamicina/biossíntese
Streptomyces/genética
[Mh] Termos MeSH secundário: Proteínas de Bactérias/metabolismo
DNA Bacteriano/metabolismo
Proteínas de Membrana/metabolismo
Estrutura Terciária de Proteína
Streptomyces/metabolismo
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (DNA, Bacterial); 0 (Membrane Proteins); 0 (Pristinamycin)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:150612
[Lr] Data última revisão:
150612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150613
[St] Status:MEDLINE


  8 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25957493
[Au] Autor:Wang W; Tian J; Li L; Ge M; Zhu H; Zheng G; Huang H; Ruan L; Jiang W; Lu Y
[Ad] Endereço:Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200032, People's Republic of China.
[Ti] Título:Identification of two novel regulatory genes involved in pristinamycin biosynthesis and elucidation of the mechanism for AtrA-p-mediated regulation in Streptomyces pristinaespiralis.
[So] Source:Appl Microbiol Biotechnol;99(17):7151-64, 2015 Sep.
[Is] ISSN:1432-0614
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:In this study, using a transposon-based strategy, two novel regulatory genes were identified as being involved in the biosynthesis of both pristinamycin I (PI) and II (PII) in Streptomyces pristinaespiralis, including a TetR-family regulatory gene atrA-p (SSDG_00466) and an orphan histidine kinase gene SSDG_02492. The mechanism by which AtrA-p exerted a positive role in pristinamycin production was elucidated. We showed that deletion of atrA-p resulted in a delayed production of both PI and PII as well as reduced PII production. Transcriptional analysis integrated with electrophoretic mobility shift assays (EMSAs) demonstrated that AtrA-p played a positive role in pristinamycin production by directly activating the transcription of two cluster-situated regulatory genes, spbR and papR5, which encode a γ-butyrolactone receptor protein and a TetR-family repressor, respectively. The precise AtrA-p-binding sites upstream of these two targets were determined, which allowed the identification of a relatively conserved binding motif comprising two 5-nt inverted repeats separated by a variable 5-nt sequence (5'-GGAAT-n5-ATTCC-3') possibly required for the regulation of AtrA-like regulators in Streptomyces. Base substitutions of the AtrA-p-binding sites on the genome caused similar decreases in spbR and papR5 transcription as those observed in ∆atrA-p. Taken together, herein, a novel mechanism for AtrA-dependent regulation of antibiotic biosynthesis was revealed in S. pristinaespiralis, which is distinct from those of its homologs, AtrA-c from Streptomyces coelicolor, AtrA-g from Streptomyces griseus, and AtrA from Streptomyces roseosporus that perform their effects in antibiotic biosynthesis directly via pathway-specific activator genes or the biosynthetic structural genes.
[Mh] Termos MeSH primário: Antibacterianos/biossíntese
Regulação Bacteriana da Expressão Gênica
Genes Reguladores
Pristinamicina/biossíntese
Streptomyces/genética
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: Sítios de Ligação
Elementos de DNA Transponíveis
Ensaio de Desvio de Mobilidade Eletroforética
Deleção de Genes
Perfilação da Expressão Gênica
Redes Reguladoras de Genes
Mutagênese Insercional
Regiões Promotoras Genéticas
Ligação Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (DNA Transposable Elements); 0 (Pristinamycin)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150814
[Lr] Data última revisão:
150814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150511
[St] Status:MEDLINE
[do] DOI:10.1007/s00253-015-6638-6


  9 / 101 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25868645
[Au] Autor:Zhao Y; Feng R; Zheng G; Tian J; Ruan L; Ge M; Jiang W; Lu Y
[Ad] Endereço:Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
[Ti] Título:Involvement of the TetR-Type Regulator PaaR in the Regulation of Pristinamycin I Biosynthesis through an Effect on Precursor Supply in Streptomyces pristinaespiralis.
[So] Source:J Bacteriol;197(12):2062-71, 2015 Jun 15.
[Is] ISSN:1098-5530
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Pristinamycin I (PI), produced by Streptomyces pristinaespiralis, is a streptogramin type B antibiotic, which contains two proteinogenic and five aproteinogenic amino acid precursors. PI is coproduced with pristinamycin II (PII), a member of streptogramin type A antibiotics. The PI biosynthetic gene cluster has been cloned and characterized. However, thus far little is understood about the regulation of PI biosynthesis. In this study, a TetR family regulator (encoded by SSDG_03033) was identified as playing a positive role in PI biosynthesis. Its homologue, PaaR, from Corynebacterium glutamicum serves as a transcriptional repressor of the paa genes involved in phenylacetic acid (PAA) catabolism. Herein, we also designated the identified regulator as PaaR. Deletion of paaR led to an approximately 70% decrease in PI production but had little effect on PII biosynthesis. Identical to the function of its homologue from C. glutamicum, PaaR is also involved in the suppression of paa expression. Given that phenylacetyl coenzyme A (PA-CoA) is the common intermediate of the PAA catabolic pathway and the biosynthetic pathway of L-phenylglycine (L-Phg), the last amino acid precursor for PI biosynthesis, we proposed that derepression of the transcription of paa genes in a ΔpaaR mutant possibly diverts more PA-CoA to the PAA catabolic pathway, thereby with less PA-CoA metabolic flux toward L-Phg formation, thus resulting in lower PI titers. This hypothesis was verified by the observations that PI production of a ΔpaaR mutant was restored by L-Phg supplementation as well as by deletion of the paaABCDE operon in the ΔpaaR mutant. Altogether, this study provides new insights into the regulation of PI biosynthesis by S. pristinaespiralis. IMPORTANCE: A better understanding of the regulation mechanisms for antibiotic biosynthesis will provide valuable clues for Streptomyces strain improvement. Herein, a TetR family regulator PaaR, which serves as the repressor of the transcription of paa genes involved in phenylacetic acid (PAA) catabolism, was identified as playing a positive role in the regulation of pristinamycin I (PI) by affecting the supply of one of seven amino acid precursors, L-phenylglycine, in Streptomyces pristinaespiralis. To our knowledge, this is the first report describing the interplay between PAA catabolism and antibiotic biosynthesis in Streptomyces strains. Considering that the PAA catabolic pathway and its regulation by PaaR are widespread in antibiotic-producing actinomycetes, it could be suggested that PaaR-dependent regulation of antibiotic biosynthesis might commonly exist.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Regulação Bacteriana da Expressão Gênica/fisiologia
Genes Reguladores/fisiologia
Pristinamicina/biossíntese
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: Acetilcoenzima A/genética
Acetilcoenzima A/metabolismo
Proteínas de Bactérias/genética
Deleção de Genes
Glicina/análogos & derivados
Glicina/metabolismo
Estrutura Molecular
Pristinamicina/química
Pristinamicina/metabolismo
Transcrição Genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Pristinamycin); 69-91-0 (2-phenylglycine); 72-89-9 (Acetyl Coenzyme A); 7532-39-0 (phenylacetyl-coenzyme A); TE7660XO1C (Glycine)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:151201
[Lr] Data última revisão:
151201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150415
[St] Status:MEDLINE
[do] DOI:10.1128/JB.00045-15


  10 / 101 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25694645
[Au] Autor:Virot E; Servien E; Laurent F; Ferry T; Lyon Bone and Joint Infection Study Group
[Ad] Endereço:Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
[Ti] Título:Reactivation of Clostridium tertium bone infection 30 years after the Iran-Iraq war.
[So] Source:BMJ Case Rep;2015, 2015 Feb 18.
[Is] ISSN:1757-790X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Infecções por Clostridium/complicações
Infecções por Clostridium/diagnóstico
Clostridium tertium/isolamento & purificação
Osteomielite/diagnóstico
Osteomielite/etiologia
Guerra
[Mh] Termos MeSH secundário: Adulto
Amoxicilina/uso terapêutico
Antibacterianos/uso terapêutico
Bombas (Dispositivos Explosivos)
Infecções por Clostridium/tratamento farmacológico
Corpos Estranhos/diagnóstico
Corpos Estranhos/cirurgia
Seres Humanos
Irã (Geográfico)
Iraque
Joelho/diagnóstico por imagem
Masculino
Osteomielite/tratamento farmacológico
Pristinamicina/uso terapêutico
Cintilografia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Pristinamycin); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150220
[St] Status:MEDLINE



página 1 de 11 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde